B. Riley Forecasts OptimizeRx’s Q1 Earnings (NASDAQ:OPRX)

OptimizeRx Co. (NASDAQ:OPRX) – Equities researchers at B. Riley issued their Q1 2025 earnings estimates for OptimizeRx in a report released on Wednesday, March 12th. B. Riley analyst A. Schock expects that the company will post earnings per share of ($0.34) for the quarter. B. Riley has a “Strong-Buy” rating on the stock. The consensus estimate for OptimizeRx’s current full-year earnings is ($0.33) per share. B. Riley also issued estimates for OptimizeRx’s Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at $0.05 EPS, Q4 2025 earnings at $0.19 EPS and FY2025 earnings at ($0.27) EPS.

Several other equities analysts have also recently commented on the company. Stephens assumed coverage on OptimizeRx in a research note on Friday, December 20th. They set an “equal weight” rating and a $5.50 target price for the company. JMP Securities reiterated a “market outperform” rating and set a $8.00 target price on shares of OptimizeRx in a research note on Thursday, February 6th. Lake Street Capital reiterated a “buy” rating and set a $11.00 target price on shares of OptimizeRx in a research note on Tuesday, December 24th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $6.00 target price (down from $7.00) on shares of OptimizeRx in a research note on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $9.06.

OptimizeRx Stock Up 9.1 %

Shares of NASDAQ:OPRX opened at $9.02 on Monday. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29. OptimizeRx has a 52-week low of $3.78 and a 52-week high of $14.13. The company has a 50 day moving average of $5.64 and a two-hundred day moving average of $5.90. The company has a market capitalization of $166.16 million, a price-to-earnings ratio of -6.78 and a beta of 1.31.

Hedge Funds Weigh In On OptimizeRx

Several large investors have recently added to or reduced their stakes in OPRX. Janney Montgomery Scott LLC bought a new position in OptimizeRx during the third quarter worth $810,000. Quest Partners LLC lifted its stake in OptimizeRx by 15,965.6% during the third quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock worth $76,000 after purchasing an additional 9,739 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in OptimizeRx by 189.2% during the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock worth $28,000 after purchasing an additional 2,414 shares during the last quarter. Barclays PLC lifted its stake in OptimizeRx by 358.5% during the third quarter. Barclays PLC now owns 26,934 shares of the company’s stock worth $208,000 after purchasing an additional 21,060 shares during the last quarter. Finally, Bullseye Asset Management LLC lifted its stake in OptimizeRx by 55.6% during the third quarter. Bullseye Asset Management LLC now owns 214,046 shares of the company’s stock worth $1,652,000 after purchasing an additional 76,458 shares during the last quarter. 76.47% of the stock is currently owned by institutional investors.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.